Loading organizations...
Intelligencia AI is a technology company.
Intelligencia AI provides an artificial intelligence platform to de-risk drug development. Its core product employs machine learning algorithms and extensive clinical data to assess, quantify, and mitigate risks within clinical trials. This approach combines data science with deep life sciences expertise, offering pharmaceutical and biotechnology companies crucial insights for optimizing portfolio strategies and enhancing decision-making.
Founded in 2017 by Dimitrios Skaltsas and Vangelis Vergetis, Intelligencia AI originated from the insight that advanced AI could significantly reduce pharmaceutical R&D failure rates. The founders, leveraging their combined backgrounds, established a platform to address uncertainties in bringing new therapies to market, aiming for improved efficiency.
The company serves pharmaceutical and biotechnology organizations optimizing drug development pipelines. By delivering predictive analytics and strategic intelligence, the platform empowers clients to make data-driven decisions on asset prioritization and clinical trial design. Intelligencia AI's vision is to transform the drug development landscape, accelerating the efficient delivery of innovative treatments to patients.
Intelligencia AI has raised $16.0M across 2 funding rounds.
Intelligencia AI has raised $16.0M in total across 2 funding rounds.
Intelligencia AI is an AI-driven technology company that builds SaaS-based solutions to de-risk drug development for pharmaceutical and biotechnology firms. Its core products, such as Portfolio Optimizer, Asset Optimizer, and BD&L Navigator, predict clinical trial outcomes, assess probability of technical and regulatory success (PTRS), optimize portfolios, and identify external assets, serving large global pharma companies and mid-sized biotechs.[1][2][3] By leveraging curated clinical data, proprietary ontologies, and patented AI models, the company tackles high drug development costs, long timelines, and low ROI through unbiased, transparent risk assessments with over 80% prospective accuracy.[2][3][4][6] Founded around 2017-2018 and headquartered in New York with offices in Athens, Greece, it employs 110 people, reported $23.1M revenue, raised $12M in Series A funding, and ranked No. 1819 on the 2024 Inc. 5000 with 287% three-year growth.[2][3][4][5]
Intelligencia AI was founded in 2017 (with some sources citing 2018) by Dimitrios Skaltsas, its CEO and co-founder, who brought over a decade of healthcare and life sciences leadership experience before launching the venture.[1][2][4] Emerging from the founders' recognition of inefficiencies in the $1.5 trillion pharmaceutical industry—particularly risky, costly drug development—the company assembled a global, interdisciplinary team of data scientists, clinical experts, and biomedical researchers.[4] Early milestones include a 2021 Series A funding round, a strategic partnership with ZS (a global services firm), and Forbes recognition as a Top AI Company to Watch; in 2024, it secured a U.S. patent for ML techniques predicting FDA approval likelihood and earned Inc. 5000 honors.[3][4]
Intelligencia AI rides the AI-for-biopharma wave, capitalizing on surging demand for data-driven tools amid rising drug development failures (90%+ attrition rates) and costs exceeding $2B per asset. Its timing aligns with post-2020 AI advancements in healthcare, regulatory nods to AI (e.g., FDA pilots), and biopharma's digital transformation push, fueled by investor interest in de-risking startups.[2][3][4] Market forces like personalized medicine, real-world evidence needs, and M&A activity favor its external innovation tools, while its patented tech sets it apart from competitors like BioMedTracker.[1] The company influences the ecosystem by accelerating therapies to patients, standardizing risk assessment, and enabling bolder portfolio decisions for 110+ employees' global operations.[2][4][6]
Intelligencia AI's momentum—Inc. 5000 ranking, patent wins, and pharma partnerships—positions it for expansion into more therapeutic areas and adjacent services like real-world evidence analytics. Trends like multimodal AI, federated learning for data privacy, and AI regulatory harmonization will amplify its edge, potentially scaling revenue beyond $23M via enterprise deals. As biopharma chases efficiency in a high-interest-rate world, its unbiased PTRS tools could evolve influence from niche advisor to industry standard, bringing life-changing drugs faster while sustaining 200%+ growth.[3][5][6] This de-risking pioneer exemplifies how AI transforms pharma's high-stakes gamble into calculated precision.
Intelligencia AI has raised $16.0M in total across 2 funding rounds.
Intelligencia AI's investors include Danchen Zhao, Big Pi Ventures, Synetro Group, Pratap Khedkar, SmartStart Fund.
Intelligencia AI has raised $16.0M across 2 funding rounds. Most recently, it raised $12.0M Series A in August 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 10, 2021 | $12.0M Series A | Danchen Zhao | Big Pi Ventures, Synetro Group, Pratap Khedkar |
| Nov 1, 2018 | $4.0M Seed | SmartStart Fund |